Read AndrewGreenBull's blog in RSS
May 27, 2010
Share This
May 30
Targeted Genetics Corporation (TGEN)
Although major indices in the U.S. have lost more than 10% since April’s high, TGEN still has 50% gains in the same period.
On Apr 28, 2010, TGEN announced that its licensing partner, Celladon Corporation, had reported that the company’s first Phase II trial with MYDICAR® for the treatment of advanced heart failure had met primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.
The full data from Celladon's clinical trial will be presented at the Heart Failure Congress 2010 on May 30, 2010, and Celladon also will uncover its plans for future development of MYDICAR.TGEN could receive multiple milestone payments totaling up to $20 million plus a 10% royalty on commercial sales of MYDICAR.
Compared with MYDICAR’s future value, TGEN’s 6.61 million market capital looks attractive even in the bear market.
June 11
Aastrom Biosciences, Inc (ASTM)
ASTM will present positive interim results from the company's U.S. Phase 2b trial designated RESTORE-CLI at this year's Vascular Annual Meeting(R) of the Society for Vascular Surgery on June 11 in Boston, MA.
RESTORE-CLI is the largest double-blind, randomized cell therapy study to be conducted for critical limb ischemia or CLI, the end-stage of peripheral arterial disease.
As of March 31, 2010, the company had $22.8 million in cash and cash equivalents and short-term investments.
My take is pretty simple for this one: 3 promising drug candidates in late stage clinical trials + one orphan drug designation + $22.8 million what is enough for at least next 12 month cash utilization according to $1.4 monthly burn rate> $39 million market capital.
So why ASTM is still around 52 weeks low when it is financially stable and good news kept coming out in the past few weeks? A bear market cannot explain for this anymore.
Maybe ASTM needs some spotlight besides good data, and I believe that Boston is the right place to go.
(To be continued)